A new #SciencePerspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.
Teacher, Clinical Supervisor, [AIdvisor]
Retired Clinical Associate Professor, Psychiatry, University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 